Relapse after First-Line Fixed Duration Ibrutinib plus Venetoclax: High Response Rates to Ibrutinib Retreatment and Absence of BTK Mutations in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) with up to 5 Years of Follow-up in the Phase 2 Captivate Study

被引：0
|
作者：
Ghia, Paolo [1 ,2 ]
Wierda, William G. [3 ]
Barr, Paul M. [4 ]
Kipps, Thomas J. [5 ]
Siddiqi, Tanya [6 ]
Allan, John N. [7 ]
Hunter, Zoe [8 ]
Zhou, Cathy [8 ]
Szoke, Anita [8 ]
Dean, James P. [9 ,10 ]
Tam, Constantine S. [11 ,12 ]
机构：
[1] Univ Vita Salute San Raffaele, Milan, Italy
[2] IRCCS Osped San Raffaele, Milan, Italy
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[4] Univ Rochester, Med Ctr, Wilmot Canc Inst, Rochester, NY USA
[5] UC San Diego Moores Canc Ctr, Duarte, CA USA
[6] City Hope Natl Med Ctr, Duarte, CA USA
[7] Weill Cornell Med, Long Isl City, NY USA
[8] AbbVie, N Chicago, IL USA
[9] AbbVie, IMBRUVICA, N Chicago, IL USA
[10] AbbVie, Pediat Oncol, N Chicago, IL USA
[11] Alfred Hosp, Melbourne, Vic, Australia
[12] Monash Univ, Melbourne, Vic, Australia
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-187128
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Final analysis from RESONATE: Six-year follow-up in patients (pts) with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) on ibrutinib.
    Barr, Paul M.
    Munir, Talha
    Brown, Jennifer R.
    O'Brien, Susan Mary
    Barrientos, Jacqueline Claudia
    Reddy, Nishitha M.
    Coutre, Steven
    Tam, Constantine Si Lun
    Mulligan, Stephen P.
    Jager, Ulrich
    Kipps, Thomas J.
    Moreno, Carol
    Montillo, Marco
    Burger, Jan Andreas
    Byrd, John C.
    Hillmen, Peter
    Dai, Sandra
    Szoke, Anita
    Dean, James P.
    Woyach, Jennifer Ann
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [42] Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
    Barr, Paul M.
    Owen, Carolyn
    Robak, Tadeusz
    Tedeschi, Alessandra
    Bairey, Osnat
    Burger, Jan A.
    Hillmen, Peter
    Coutre, Steve E.
    Dearden, Claire
    Grosicki, Sebastian
    McCarthy, Helen
    Li, Jian-Yong
    Offner, Fritz
    Moreno, Carol
    Zhou, Cathy
    Hsu, Emily
    Szoke, Anita
    Kipps, Thomas J.
    Ghia, Paolo
    BLOOD ADVANCES, 2022, 6 (11) : 3440 - 3450
  • [43] Ibrutinib for first-line treatment of chronic lymphocytic leukemia in patients aged ≥65 year of age: results with 5 years of follow-up for the RESONATE-2 study
    Tedeschi, Alessandra
    Burger, Jan A.
    Barr, Paul
    Robak, Tadeusz
    Owen, Carolyn
    Ghia, Paolo
    Bairey, Osnat
    Hillmen, Peter
    Coutre, Steven
    Devereux, Stephen
    Grosicki, Sebastian
    McCarthy, Helen
    Li, Jianyong
    Simpson, David
    Offner, Fritz
    Moreno, Carol
    Dai, Xiaoxian
    Lal, Indu
    Dean, James
    Kipps, Thomas J.
    LEUKEMIA & LYMPHOMA, 2020, 61 : 38 - 40
  • [44] FIVE YEARS OF FOLLOW-UP FROM THE PHASE 3 RESONATE-2 STUDY AND NURSING EXPERIENCE WITH PATIENTS RECEIVING FIRST-LINE IBRUTINIB FOR CHRONIC LYMPHOCYTIC LEUKEMIA
    Greenberg, Edythe M.
    Settlemire, Milan
    Lal, Indu
    Amaya-Chanaga, Carlos
    Coutre, Steven
    Burger, Jan A.
    ONCOLOGY NURSING FORUM, 2020, 47 (02)
  • [45] Three-year follow-up of patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) receiving ibrutinib plus bendamustine and rituximab (BR) versus placebo plus BR: an update of the HELIOS study
    Hallek, Michael
    Fraser, Graeme
    Cramer, Paula
    Demirkan, Fatih
    Silva, Rodrigo Santucci
    Grosicki, Sebastian
    Janssens, Ann
    Pristupa, Aleksander
    Mayer, Jiri
    Dilhuydy, Marie Sarah
    Loscertales, Javier
    Bartlett, Nancy
    Avigdor, Abraham
    Rule, Simon
    Sun, Steven
    Mahler, Michelle
    Phelps, Charles
    Salman, Mariya
    Howes, Angela
    Chanan-Khan, Asher
    LEUKEMIA & LYMPHOMA, 2017, 58 : 192 - 194
  • [46] Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia
    Rogers, Kerry A.
    Huang, Ying
    Ruppert, Amy S.
    Abruzzo, Lynne V.
    Bhat, Seema A.
    Hoffman, Corinne
    Maddocks, Kami J.
    Lozanski, Gerard
    Kittai, Adam S.
    Moran, Mollie E.
    Reid, Mark
    Woyach, Jennifer A.
    Byrd, John C.
    BLOOD, 2020, 136
  • [47] Up to 7 Years of Follow-up of Single-Agent Ibrutinib in the Phase 1b/2 PCYC-1102 Trial of First Line and Relapsed/Refractory Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    Byrd, John C.
    Furman, Richard R.
    Coutre, Steven
    Flinn, Ian W.
    Burger, Jan A.
    Blum, Kristie A.
    Sharman, Jeff
    Wierda, William G.
    Zhao, Weiqiang
    Heerema, Nyla A.
    Luan, Ying
    Liu, Emily A.
    Dean, James P.
    O'Brien, Susan M.
    BLOOD, 2018, 132
  • [48] A phase 1b/2 study evaluating activity and tolerability of the BTK inhibitor ibrutinib in combination with ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases.
    Jaglowski, Samantha Mary
    Jones, Jeffrey Alan
    Flynn, Joseph M.
    Andritsos, Leslie A.
    Maddocks, Kami J.
    Woyach, Jennifer Ann
    Blum, Kristie A.
    Grever, Michael R.
    Geyer, Susan Michelle
    Heerema, Nyla A.
    Lozanski, Gerard
    Stefanos, Mona
    Hall, Nathan
    Nagar, Veena
    Munneke, Brian
    West, Jamie-Sue
    Neuenburg, Jutta
    James, Danelle Frances
    Johnson, Amy J.
    Byrd, John C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [49] First Interim Analysis Of ALPINE Study: Results Of A Phase 3 Randomized Study Of Zanubrutinib Vs Ibrutinib In Patients With Relapsed / Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL / SLL)
    Hillmen, Peter
    Eichhorst, Barbara
    Brown, Jennifer R.
    Lamanna, Nicole
    O'brien, Susan
    Tam, Constantine S.
    Qiu, Lugui
    Kazmierczak, Maciej
    Zhou, Keshu
    Simkovic, Martin
    Mayer, Jiri
    Gillespie-Twardy, Amanda
    Shadman, Mazyar
    Ferrajoli, Alessandra
    Ganly, Peter S.
    Weinkove, Robert
    Salmi, Tommi
    Ji, Meng
    Yecies, Jessica
    Wu, Kenneth
    Novotny, William
    Huang, Jane
    Jurczak, Wojciech
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 143 - 144
  • [50] Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study
    Wierda, William G.
    Allan, John N.
    Siddiqi, Tanya
    Kipps, Thomas J.
    Opat, Stephen
    Tedeschi, Alessandra
    Badoux, Xavier C.
    Kuss, Bryone J.
    Jackson, Sharon
    Moreno, Carol
    Jacobs, Ryan
    Pagel, John M.
    Flinn, Ian
    Pak, Yvonne
    Zhou, Cathy
    Szafer-Glusman, Edith
    Ninomoto, Joi
    Dean, James P.
    James, Danelle F.
    Ghia, Paolo
    Tam, Constantine S.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (34) : 3853 - +
12345